Walmart Now Sells Biomerica EZ Detect ™ Colorectal

  • Simple 2-minute home test finds warning sign of colorectal cancer

IRVINE, Calif., October 01, 2021 (GLOBE NEWSWIRE) – Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) today announced that it has entered into a general merchandise supplier agreement with Walmart for sale The Company’s EZ Detect ™ Colorectal Disease Test within the Walmart retail system. The company has now shipped its first orders of the EZ Detect ™ product to Walmart, and as of this week Walmart has started selling the product through its online sales channel ( EZ-Detect Colon Disease Test Kit / 577079744).

Biomerica is also in the final stages of working with Walmart to store and sell the EZ Detect product on their store shelves. In addition, the Company is in negotiations with several major partners for the distribution of the EZ Detect ™ product in Asia, Europe and the Middle East.

The EZ Detect ™ Colon Disease Test is the simplest home test to detect occult (hidden) blood in a person’s stool, which can be a warning sign of colorectal disease, including colon and rectal cancers. The test does not require stool handling or dietary restrictions. A person simply places an EZ Detect ™ test pad in the toilet after a bowel movement. A change in color of the swab to blue / green, which would appear within two minutes, indicates the presence of blood in the stool. The tampon is then simply flushed down the toilet.

Colorectal cancer (“CRC”) is the second leading cause of cancer death in the United States. In 2020, around 147,950 people would be diagnosed with CRC and around 53,200 would die from the disease, including 17,930 cases and 3,640 deaths in people under the age of 50. [1].

In a study by Johns Hopkins University, EZ Detect ™ was preferred 10: 1 by patients over another test for fecal occult blood. Published studies have also indicated that the best colorectal screening test is “the one that gets done”. [2] Other colorectal screening tests involve handling the stool and delivering or sending the stool sample to a laboratory for processing. Stool manipulation means that a high percentage of these competing tests are never performed by patients[3]. EZ Detect ™ does not require stool manipulation, is simple to perform, and delivers results in just two minutes.

“With the current COVID-19 pandemic, consumers have become much more aware of home diagnostic tests and are more comfortable performing these tests. For this reason, many global retailers are focusing more on selling home health solutions. This growing trend presents many opportunities for our EZ Detect ™ colorectal disease test, our Aware ™ breast self-examination product and other products we manufacture for home use. While there are other choices for colorectal disease screening, EZ Detect ™ offers the only alternative that does not require stool manipulation, making our test more attractive and easier to perform from a consumer perspective. . In addition, EZ Detect’s online sales agreement with Walmart could bring significant exposure to the product here in the United States, ”commented Zack Irani, CEO of Biomerica.

For more information on the EZ Detect product, please visit

About Biomerica (NASDAQ: BMRA)

Biomerica, Inc. ( is a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostics and therapeutics for use at the point of care (home and physician’s offices) and in clinics. hospitals / clinics. laboratories for the detection and / or treatment of medical conditions and diseases. The Company’s products are designed to improve the health and well-being of individuals, while reducing total health care costs. The main focus of Biomerica is gastrointestinal and inflammatory diseases where the Company has several diagnostic and therapeutic products in development.

1. Siegel, RL, et al., Colorectal Cancer Statistics, 2020. CA Cancer J Clin, 2020. 70(3): p. 145-164.
2. Lansdorp-Vogelaar, I., AB Knudsen and H. Brenner, Cost-effectiveness of colorectal cancer screening – an overview. Best Practice Res Clin Gastroenterol, 2010. 24(4): p. 439-49.
3. Navarro, M., et al., Colorectal cancer screening programs around the world in 2016: update. World J Gastroenterol, 2017. 23(20): p. 3632-3642.

The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Certain information included in this press release (as well as information included in oral or other written statements made or to be made by Biomerica) contains forward-looking statements, such as statements relating to the effectiveness of the EZ Detect system. of the Company and other tests, FDA clearance of the Company’s products, possible EZ Detect in-store offerings, timeliness of test results, negotiations with international channel partners, uniqueness of the Company’s products, accuracy of product test results, price of the company’s test kits, demand for domestic or international orders, potential revenue from the sale of current or future products, availability of the company’s test kits, and protection by patent on one of the Company’s products or technologies. Such forward-looking information involves significant risks and uncertainties that could significantly affect expected results in the future, including, without limitation: the results of studies testing the effectiveness of the Company’s tests, InFoods tests and other products; regulatory approvals required before the Company’s products are marketed; the availability of test kits and other Company products; the capacity, resources and other constraints of our suppliers; dependence on our third party manufacturers; dependence on international shipping carriers; government import / export regulations; demand for our various tests and other products; competition from other similar products and from competitors who have much more financial and other resources; government virus control regulations that make it difficult or impossible for the company to maintain current operations; the Company’s ability to comply with current and future regulations in the countries where our products are manufactured and sold; and the Company’s ability to obtain patent protection on all aspects of its rapid test technologies. Therefore, these results may differ materially from those expressed in forward-looking statements made by or on behalf of Biomerica. In addition, potential risks and uncertainties include, among others, fluctuations in the Company’s operating results due to its business model and expansion plans, slowdowns in international and / or domestic economies, the ability to the Company to raise additional capital, the competitive environment in which the Company competes and the Company’s dependence on strategic relationships. The Company has no obligation to update any forward-looking statements after the date of this press release.

Corporate contact:

John Nesbett / Jennifer Belodeau
IMS Investor Relations
[email protected]

Source: Biomerica, Inc.

Source link


Comments are closed.